Stockscreener 앱 받기
8.68
8.93%
-0.84
시간 외 거래:
8.68
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Dyne Therapeutics (DYN) Receives Continued Buy Rating from Guggenheim | DYN Stock News - GuruFocus
Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN) - Seeking Alpha
Dyne Therapeutics (DYN): Baird Lowers Price Target to $32 | DYN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent
Dyne at ‘attractive entry point’ following pullback, says Chardan - Yahoo Finance
Dyne Therapeutics (DYN) Price Target Reduced by Baird | DYN Stoc - GuruFocus
H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock - Investing.com
Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback - The Pharma Letter
Dyne’s DM1 treatment receives FDA breakthrough designation By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revi - GuruFocus
Dyne Therapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – DYN - Business Wire
Dyne Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Dyne Therapeutics (DYN) Boosted by DYNE-101 Program Updates | DY - GuruFocus
Dyne Therapeutics (DYN) Rating and Price Target Maintained by Ch - GuruFocus
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Benzinga
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | D - GuruFocus
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathw - GuruFocus
Transcript : Dyne Therapeutics, Inc.Special Call - MarketScreener
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathway Update | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Faces Setback with DYNE-101 Approval Del - GuruFocus
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Shares Drop Amid Clinical Trial Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | DYN Stock News - GuruFocus
Dyne stock on revised plan for clinical program (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics (DYN) Gains FDA Breakthrough Therapy Designati - GuruFocus
Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy - MarketScreener
Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 - Investing.com Nigeria
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Granted Breakthrough Therapy Designation - TipRanks
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - The Manila Times
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
FDA Breakthrough: Dyne's DM1 Drug Shows 20% Muscle Strength Gain in Latest Trial Data - Stock Titan
Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire
Dyne Therapeutics To Host Investor Conference Call And Webcast - marketscreener.com
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET | DYN Stock News - GuruFocus
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewswire
Dyne Therapeutics to Reveal Crucial Data on DYNE-101 DM1 Treatment: Key Clinical Updates Coming Tomorrow - Stock Titan
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James - Defense World
Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus
Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada
Dyne Therapeutics officer sells shares worth $1,949 - Investing.com
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com
Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DYNE-302 for FSHD | DYN Stock News - GuruFocus
Dyne Therapeutics to Present New Preclinical Data in Facioscapul - GuruFocus
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress - The Manila Times
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress | DYN Stock News - GuruFocus
Dyne Therapeutics Announces Functional Improvement of DYNE-302 in FSHD Preclinical Model - Nasdaq
Breakthrough: New FSHD Treatment Restores Muscle Function in Single Dose, Dyne Reports - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in May - Defense World
0.27%
0.50%
자본화:
|
볼륨(24시간):